All In Biotech

Drug Trial Radar · NCT04330638

Treatment of COVID-19 Patients With Anti-interleukin Drugs

A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome

Last checked: Nov 20, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

342

Actual

Start

Apr 3, 2020

Primary completion

Dec 20, 2020

Study completion May 21, 2021

Sponsor

Lead sponsor
University Hospital, GhentAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Belgium Health Care Knowledge Centre
First posted
Apr 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure and systemic cytokine release syndrome

Conditions

  • COVID-19

Interventions

  • Usual CareOther

    Usual Care

  • AnakinraDrug

    Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first

  • SiltuximabDrug

    Siltuximab will be given via single IV infusion at a dose of 11 mg/kg

  • TocilizumabDrug

    Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinical ImprovementTime frame: at day 15

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • AZ Sint-Jan Brugge

    Bruges, Belgium

  • University Hospital Saint-Pierre

    Brussels, Belgium

  • Erasmus University Hospital

    Brussels, Belgium

  • University Hospital Saint-Luc

    Brussels, Belgium

  • University Hospital Antwerp

    Edegem, Belgium

  • Ziekenhuis Oost-Limurg

    Genk, Belgium

  • AZ Sint-Lucas

    Ghent, Belgium

  • University Hospital Ghent

    Ghent, Belgium

  • Jessa ZH

    Hasselt, Belgium

  • University Hospital Brussels

    Jette, Belgium

  • CHU Tivoli

    La Louvière, Belgium

  • CHR de la Citadelle

    Liège, Belgium

  • University Hospital Liège

    Liège, Belgium

  • Cliniques Saint-Pierre Ottignies

    Ottignies-Louvain-la-Neuve, Belgium

  • AZ Delta

    Roeselare, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.